Article Text

Download PDFPDF

Extrahepatic portal vein thrombosis in a pregnant patient with COVID-19: a rare thrombotic event survivor
  1. Mukta Agarwal1,
  2. Smita Singh1,
  3. Upasna Sinha2 and
  4. Divendu Bhushan3
  1. 1Obstetrics and Gynaecology, AIIMS Patna, Patna, Bihar, India
  2. 2Department of Radiodiagnosis, AIIMS Patna, Patna, Bihar, India
  3. 3General Medicine, All India Institute of Medical Sciences Patna, Patna, India
  1. Correspondence to Dr Divendu Bhushan; drdivendubhushan{at}


A COVID-19 infection predisposes the infected person to thrombotic events. Myocardial infarction, acute limb ischaemia, mesenteric artery thrombosis and pulmonary embolism are all well-documented complications of this infection. Here we describe a pregnant patient who presented with obstructed labour with asymptomatic COVID-19 infection and developed ascites during the postoperative period. Further work-up of the patient revealed portal hypertension due to portal vein thrombosis (PVT). As the patient was healthy before this index pregnancy, a causative link between COVID-19 and PVT cannot be ruled out. Her COVID-19 infection progressed to a moderate disease. She was managed with steroids and appropriate antibiotics for secondary bacterial peritonitis. She was finally discharged after 2.5 months of multidisciplinary treatment. This is a case of a survivor of complications due to pregnancy, COVID-19 and extrahepatic portal vein obstruction.

  • COVID-19
  • pregnancy
  • adult intensive care

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Extrahepatic portal vein thrombosis (EHPVT) is an obstruction of the extrahepatic vein with or without involvement of the intrahepatic portal vein or the splenic or superior mesenteric veins.1 Globally, cirrhosis of the liver is the foremost cause of portal hypertension, followed by extrahepatic portal vein obstruction (EHPVO). In developing countries EHPVO accounts for 35%–40% of cases of portal hypertension. Most cases of non-cirrhotic portal vein thrombosis are caused by more than one factor, with thrombophilic conditions accounting for 60% of cases. Pathophysiological research revealed that a COVID-19 infection is a cause of thrombosis, and therefore if anyone develops COVID-19 during pregnancy the patient will have higher chances of thrombotic events.

Case presentation

A 28-year-old primigravida was referred to a tertiary care dedicated COVID-19 hospital as a case of full-term pregnancy with asymptomatic COVID-19 infection. On examination, her vitals were stable with mild hypertension (150/90 mm Hg) and generalised body swelling. Obstetric examination revealed a single live fetus with features of obstructed labour. Hence, the patient was taken for emergency lower segment caesarean section. A healthy baby of birth weight 3.0 kg with Apgar score of 9/10 was delivered.

The immediate postoperative period was uneventful. Antibiotics (ceftriaxone and metronidazole), low molecular weight heparin (LMWH) and supportive treatment as per the COVID-19 treatment protocol were prescribed to the patient. On postoperative day (POD) 5, the patient complained of acute abdominal pain. Her abdomen was distended and tender and abdominal girth showed an increasing trend. The surgical site was also found to be indurated. She later developed high-grade fever. Antibiotics were upgraded to piperacillin-tazobactam. The patient was subjected to ultrasonography (USG) of the abdomen and further to contrast-enhanced CT (CECT) of the abdomen.

The USG showed a liver span of 12.8 cm. The main portal vein was not visualised, no flow on colour Doppler could be appreciated, periportal cuffing was present, and the portal vein at the hilum was replaced by multiple tortuous collaterals. Neither the intrahepatic biliary radical dilatation nor surface irregularity of the liver was evident. The spleen was enlarged (14.7 cm), with multiple dilated collaterals at the splenic hilum, suggestive of EHPVO. Gross ascites and bilateral minimal pleural effusion were also seen (figure 1).

Figure 1

Ultrasonography showing portal vein thrombosis and portal cavernoma.

CECT further confirmed these findings, along with an incision site haematoma which was planned to be managed conservatively (figure 2).

Figure 2

Contrast-enhanced CT of the abdomen showing multiple collaterals forming portal cavernoma.

Various laboratory reports are elaborated sequentially in table 1.

Table 1

Serial investigations of the patient

On POD 7, the patient was transferred to the intensive care unit in view of tachypnoea, fever and ascites. Ascitic fluid examination showed a higher Total Leucocyte Count (TLC) count of 4000 cells/mm3 with 60% neutrophils and low Adenosine deaminase (ADA). Serum ascitic albumin gradient was >1.1 and Gram staining and Ziehl- Neelsen (ZN) staining showed no micro-organism except for a few pus cells. Blood culture and ascitic fluid culture were sterile, so a diagnosis of secondary bacterial peritonitis (postcaesarean section) with severe anaemia and thrombocytopaenia secondary to non-cirrhotic portal vein thrombosis was made. Wound dehiscence was present with wound site haematoma, which was managed by daily sterile surgical dressing. To relieve abdominal discomfort and breathlessness, she required intermittent therapeutic paracentesis. LMWH was stopped in view of the thrombocytopaenia. Carvedilol 3.125 mg, spironolactone 200 mg and ramipril 2.5 mg were started.

On POD 10, she developed hypoxia and required 2 L/min oxygen to maintain an oxygen saturation of >94%. She developed crepitations, mostly in the bilateral infrascapular region. She was started on 6 mg dexamethasone according to our institutional guidelines for moderate COVID-19. According to Institutional guidelines, she was started on 6 mg oral dexamethasone, injection meropenem and injection clindamycin. On POD 15, she had one episode of haematemesis, which was managed with pantoprazole infusion and terlipressin. Upper gastrointestinal endoscopy could not be done due to technical reasons during the COVID-19 period. Her oxygen requirement continued to increase further up to 6 L/min by face mask. Her condition improved gradually with the treatment. On POD 21, repeat ascitic fluid analysis showed total cell count of 100/cu mm with 80% mononuclear cells. On POD 30, her ascites began to subside and the wound haematoma resolved. The patient was maintaining oxygen saturation of >95% in room air. She received a total of 8 units of packed red blood cells (PRBC), 4 units of platelet concentrates and 12 doses (100 mL) of 20% albumin during her hospital stay.

On POD 56, the patient again developed high-grade fever and her USG revealed 500–600 cc of thick intraperitoneal collection. Doppler showed persistence of thrombus in the portal vein. USG-guided pigtail catheter was inserted to drain the collection and antibiotics (meropenem and levofloxacin) were given. After 64 days of hospitalisation, the patient was discharged in stable condition. The patient is still under follow-up and is in stable condition.

Differential diagnosis

Undiagnosed chronic liver disease, tuberculous ascites and Budd-Chiari syndrome are the main differentials. USG of the abdomen and ascitic fluid evaluation narrowed down the diagnosis.


The patient was managed with LMWH, diuretics, beta blockers, terlipressin and antibiotics for secondary bacterial peritonitis.

Outcome and follow-up

The patient was discharged and followed up monthly through telemedicine services.


COVID-19 infection is associated with raised interleukin (IL)-2, IL-7, IL-10, granulocyte-colony stimulating factor, IgG-induced protein 10, macrophage chemoattractant protein-1, macrophage inflammatory protein-1 alpha and tumour necrosis factor-α.2 These cause a hypercoagulable state, possibly via activation of endothelial cells, platelets and leucocytes, inducing tissue factors and subsequently triggering clotting cascade by activation of factor VIIa.3 4 This will lead to various thrombotic events such as pulmonary venous thromboembolism, arterial thrombosis causing acute limb ischaemia, acute coronary syndromes and mesenteric ischaemia. When combined with pregnancy the chances of thrombotic events increase. While searching the literature, we did not come across any case report of EHPVT in COVID-19. This is probably the first case report of chronic EHPVT described in COVID-19 during pregnancy.

In 2011, Aggarwal et al5 reported their observations of pregnancy in patients with EHPVO. They observed 26 such pregnancies in 14 women and found that pregnancy outcome was successful if the disease is adequately controlled. In another retrospective study, a total of 50 pregnancies with non-cirrhotic portal hypertension were reported, in which 12 were due to EHPVO.6

In a 9-year study from South India, an incidence of portal hypertension in pregnancy of 0.07% was observed, and in such patients non-cirrhotic portal hypertension accounts for 74.1% of cases. Of the patients, 54.7% were diagnosed with it along with an index pregnancy. Most of them presented with pancytopaenia and splenomegaly. Variceal bleeding occurs in 25% of cases.7 Aetiological, adult-onset EHPVO is heterogeneous but may be associated with one or more risk factors for thrombosis, such as myeloproliferative disorders or deficiency of protein C and protein S. Aggarwal et al5 found underlying hypercoagulable states in 21% of patients, whereas Mandal et al8 and Subbaiah et al1 did not find any such cause in any of their patients.

Patients with portal vein obstruction need detailed preconception counselling and evaluation. Liver functions usually remain well preserved in these patients but tend to decompensate in a few patients in the event of an increased portal blood flow and thrombogenic tendency during pregnancy.9 There are no definite guidelines for the management of such patients to date due to the paucity of evidence. Any history of variceal bleeding, jaundice, thrombocytopaenia, ascites or hypersplenism indicates poor prognosis. Pregnancy should be planned in stable liver conditions and medical termination of pregnancy (MTP) may be advised if the disease is at a decompensated stage. The American Association for the Study of Liver Diseases currently recommends screening endoscopy in the second trimester for such patients.10 Current literature (Baveno V consensus workshop) recommends endoscopic variceal ligation or banding for acute variceal bleeding.11 Pregnancy can be allowed until term, but may be terminated in case of progressive liver disease. The second stage of labour should be shortened and the third stage managed actively to prevent postpartum haemorrhage (PPH). Vaginal delivery is allowed in most cases and caesarean section is reserved only for obstetric indications. Ultrasound is the investigation of choice and shows portal cavernoma and collateral circulation. The role of anticoagulants and beta blockers in chronic EHPVO is not clear.12

Patients who are pregnant and with portal vein thrombosis pose a challenge for the clinical team and require management by multiple disciplines, including obstetricians, gastro-physicians, radiologists and intensivists. This case posed unique challenge to the treating team as both pregnancy and COVID were hypercoagulable states and no definitive treatment guidlines were available. The case was managed successfully by the combined efforts of all the specialties and a precious life was saved as a result of team work for 2 months.

Learning points

  • COVID-19 infection is a prothrombotic condition and pregnancy, being a hypercoagulable state, may act synergistically.

  • Extrahepatic portal vein obstruction is the most common cause of portal hypertension after chronic liver disease.

  • Anticoagulation is the preferred treatment for these cases.

Ethics statements



  • Contributors MA: patient care, manuscript writing. SS: patient care, collection of data. US: radiological assistance. DB: patient care, manuscript editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.